Pediatric NMOSD Observational Study
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03766347 |
Recruitment Status :
Recruiting
First Posted : December 6, 2018
Last Update Posted : June 11, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Neuromyelitis Optica NMO Spectrum Disorder |
This study is being done to collect information on the natural history of NMOSD in pediatric AQP4-IgG seropositive patients. A major restriction in performing drug studies in pediatric patients with NMOSD is limited information on the course of the disease in these patients. Collecting clinical information over the course of a 1 year observational study would inform on the natural history of the disease in these patients. A repository of pediatric patients with rare diseases can increase knowledge on the natural history of the specific disease, assist in identifying appropriate patients fulfilling specified criteria for drug studies and potentially serve as a control group.
Timepoints: Baseline, 3mo, 6mo, 9mo, 12mo (+/- 1 mo for each time point).
Baseline data:
- Demographics [age/sex/ethnicity],
- Clinical presentation information including date of initial diagnosis,
- Clinical phenotype
- Immunotherapy used current and past,
- Family history of autoimmune diseases,
- Serological data results
- Radiologic data as available
Self-Report Assessments will be:
- Current impairment, as measured by the expanded disability status scale (EDSS) score self-reported using Ratzker (1997) EDSS Self Report form,
- Quality of life as measured by the EQ-5D and Varni's (1998) PedsQL over the phone/mail/email.
At follow-up visits 3mo, 6mo, 9mo, 12mo (+/- 1 mo for each time point):
- Attacks/relapses
- Any hospitalizations
- Confirm medications and update records if changes
Self-Report Assessments at follow-up will be:
- Current impairment, as measured by the EDSS score self-reported using Ratzker (1997) EDSS Self Report form,
- Quality of life as measured by the EQ-5D and PedsQL over the phone/mail/email.
Study Type : | Observational [Patient Registry] |
Estimated Enrollment : | 100 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Target Follow-Up Duration: | 1 Year |
Official Title: | Pediatric Neuromyelitis Optica Spectrum Disorder (NMOSD) 1 Year Observational Study |
Actual Study Start Date : | February 1, 2018 |
Estimated Primary Completion Date : | February 1, 2021 |
Estimated Study Completion Date : | February 1, 2021 |

Group/Cohort |
---|
Pediatric Neuromyelitis Optica
Participants under the age of 18 that are positive for Aquaporin-4 antibody.
|
- Time to relapse [ Time Frame: One year. ]Relapse events of NMOSD defined by clinical worsening of neurological symptoms and treatment.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 2 Years to 17 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- AQP4 positive
- Ability to give informed consent by patient or caregiver
Exclusion Criteria:
- Inability to complete required forms via phone, mail, or email.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03766347
Contact: Cara L Thomas, AA | 507-422-5563 | thomas.cara@mayo.edu | |
Contact: Katie Dunlay, BA | 507-538-5418 | dunlay.katie@mayo.edu |
United States, Minnesota | |
Mayo Clinic | Recruiting |
Rochester, Minnesota, United States, 55905 | |
Contact: Sean J. Pittock, M.D. 507-266-3196 pittock.sean@mayo.edu | |
Principal Investigator: Sean J. Pittock, M.D. |
Principal Investigator: | Sean J Pittock, M.D. | Mayo Clinic |
Responsible Party: | Sean Pittock, Prinicpal Investigator, Mayo Clinic |
ClinicalTrials.gov Identifier: | NCT03766347 |
Other Study ID Numbers: |
17-005618 |
First Posted: | December 6, 2018 Key Record Dates |
Last Update Posted: | June 11, 2020 |
Last Verified: | June 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Pediatric Aquaporin-4 AQP4 |
NMOSD NMO Neuromyelitis Optica |
Neuromyelitis Optica Myelitis, Transverse Demyelinating Autoimmune Diseases, CNS Autoimmune Diseases of the Nervous System Nervous System Diseases Optic Neuritis |
Optic Nerve Diseases Cranial Nerve Diseases Demyelinating Diseases Eye Diseases Autoimmune Diseases Immune System Diseases |